Top

Published in:

01-08-2019 | Osteoarthrosis | Review

Rheumatology training and research in Iran

Authors: Alireza Khabbazi, Mohsen Soroosh

Published in: Rheumatology International | Issue 8/2019

Abstract

Rheumatology is one of the most important clinical subspecialties in Iran. In the past 2 decades, Iran has witnessed an immense progress in the field of rheumatology training and research, which has led to an increase in the number of rheumatologists and research performed in the field of musculoskeletal disorders. These advances have made way for greater access to subspecialty care for rheumatic disorders. To write this article, we performed a systematic literature search using PubMed/MEDLINE, Web of Science, SCOPUS, Google Scholar and SID databases. In the first part of the manuscript, we will provide information about the history of rheumatology, rheumatology practice, referral system, the rheumatology training in medical schools, training of rheumatology subspecialists and post-graduate program of continuing medical education for rheumatologists in Iran as well as the Iranian Rheumatology Society. We will then focus on rheumatology research, top researchers, research centers focused on rheumatic disorders, the characteristics of common rheumatic diseases and ultimately biologics and biosimilars in Iran.

Davatchi F, Jamshidi AR, Banihashemi AT et al (2008) WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 35(7):1384PubMed

Davatchi F, Sandoughi M, Moghimi N et al (2016) Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. Int J Rheum Dis 19(11):1056–1062. https://doi.org/10.1111/1756-185X.12809 CrossRefPubMed

Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z (2013) Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci 18(9):759–766PubMedPubMedCentral

Naghavi M, Abolhassani F, Pourmalek F et al (2009) The burden of disease and injury in Iran in the year 2003. Popul Health Metr 4(1):1–19. https://doi.org/10.1186/1478-7954-7-9 CrossRef

Ministry of Health and Medical Education. Deputy of Education. http://dme.behdasht.gov.ir/index.aspx. Last updated 9 May 2019. Accessed 10 May 2019

Davatchi Fereydoun (2009) Rheumatology in Iran. Int J Rheum Dis 12:283–287. https://doi.org/10.1111/j.1756-185X.2009.01425.x CrossRefPubMed

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3 CrossRefPubMed

Iranian Rheumatology Association. About-us. http://iranianra.ir/page/142/About-us. Last updated 9 May 2019. Accessed 10 May 2019

Rheumatology Research Center. http://rrc.tums.ac.ir/page/view/id/3?lang=fa. Last updated 9 May 2019. Accessed 10 May 2019

10.

Continuing Medical Education. http://cehp.behdasht.gov.ir/index.aspx. Last updated 9 May 2019. Accessed 10 May 2019

11.

Scientology system of faculty members. http://isid.research.ac.ir. Last updated 9 May 2019. Accessed 10 May 2019

12.

Tehran University of Medical Sciences. History of School of Medicine. http://medicine.tums.ac.ir/college/fa. Last updated 10 May 2019. Accessed 10 May 2019

13.

Ministry of Health and Medical Education. Food and Drug Administration. Biologic medications. http://fda.gov.ir. Last updated 30 Apr 2018. Accessed 10 May 2019

14.

Deshpande S (2014) History of rheumatology. Med J Dr. D.Y. Patil Univ 7(2):119–123. https://doi.org/10.4103/0975-2870.126307

15.

Tehran University Medical Journal. TUMS Publications. http://tumj.tums.ac.ir. Last updated 10 May 2019. Accessed 10 May 2019

16.

Tabriz University of Medical Sciences. History. https://www.tbzmed.ac.ir/?PageID=111. Last updated 9 May 2019. Accessed 10 May 2019

17.

Wikipedia. Tabriz University of Medical Sciences. https://en.wikipedia.org/wiki/Tabriz_University_of_Medical_Sciences. Last updated 28 Nov 2018. Accessed 10 May 2019

18.

Moghimi N, Davatchi F, Rahimi E et al (2015) WHO-ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. Clin Rheumatol 34(3):535–543. https://doi.org/10.1007/s10067-013-2430-0 CrossRefPubMed

19.

Sandoughi M, Zakeri Z, Tehrani Banihashemi A et al (2013) Prevalence of musculoskeletal disorders in southeastern Iran: a WHO-ILAR COPCORD study (stage 1, urban study). Int J Rheum Dis 16(5):509–517. https://doi.org/10.1111/1756-185X.12110 CrossRefPubMed

20.

Davatchi F, Tehrani Banihashemi A, Gholami J et al (2009) The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 28(11):1267–1274. https://doi.org/10.1007/s10067-009-1234-8 CrossRefPubMed

21.

SCOPUS. Advanced search. https://www.scopus.com/search/form.uri?display=basic. Last updated 10 May 2019. Accessed 10 May 2019

22.

Kolahi S, Khabbazi A, Malek Mahdavi A et al (2017) Prevalence of musculoskeletal disorders in Azar cohort population in Northwest of Iran. Rheumatol Int 37(4):495–502. https://doi.org/10.1007/s00296-017-3661-1 CrossRefPubMed

23.

Dahaghin S, Tehrani-Banihashemi SA, Faezi ST, Jamshidi AR, Davatchi F (2009) Squatting, sitting on the floor, or cycling: are life-long daily activities risk factors for clinical knee osteoarthritis? Stage III results of a community-based study. Arthritis Rheum 61(10):1337–1342. https://doi.org/10.1002/art.24737 CrossRefPubMed

24.

Panah SH, Baharlouie H, Rezaeian ZS, Hawker G (2016) Cross-cultural adaptation and validation of the Persian version of the Intermittent and Constant Osteoarthritis Pain Measure for the knee. Iran J Nurs Midwifery Res 21(4):417–423. https://doi.org/10.4103/1735-9066.185595 CrossRefPubMedPubMedCentral

25.

Askary-Ashtiani AR, Mousavi SJ, Montazeri A, Shamsollahi S, Parnianpour M (2009) Cultural adaptation and validation of the Persian version of the Arthritis Impact Measurement Scales 2-Short Form in patients with osteoarthritis of the knee. Disabil Rehabil 31(25):2081–2087. https://doi.org/10.3109/09638280902918746 CrossRefPubMed

26.

Kordi Yoosefinejad A, Motealleh A, Babakhani M (2017) Evaluation of validity and reliability of the Persian version of the functional index of hand osteoarthritis. Rheumatol Int 37(5):719–725. https://doi.org/10.1007/s00296-016-3645-6 CrossRefPubMed

27.

Salavati M, Akhbari B, Mohammadi F, Mazaheri M, Khorrami M (2011) Knee injury and Osteoarthritis Outcome Score (KOOS); reliability and validity in competitive athletes after anterior cruciate ligament reconstruction. Osteoarthr Cartil 19(4):406–410. https://doi.org/10.1016/j.joca.2011.01.010 CrossRef

28.

Mousavi SJ, Parnianpour M, Askary-Ashtiani AR, Hadian MR, Rostamian A, Montazeri A (2009) Translation and validation study of the Persian version of the Arthritis Impact Measurement Scales 2 (AIMS2) in patients with osteoarthritis of the knee. BMC Musculoskelet Disord 10:95. https://doi.org/10.1186/1471-2474-10-95 CrossRefPubMedPubMedCentral

29.

Nadrian H, Moghimi N, Nadrian E, Moradzadeh R, Bahmanpour K, Iranpour A, Bellamy N (2012) Validity and reliability of the Persian versions of WOMAC Osteoarthritis Index and Lequesne Algofunctional Index. Clin Rheumatol 31(7):1097–1102. https://doi.org/10.1007/s10067-012-1983-7 CrossRefPubMed

30.

Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A (2016) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 28(11):1625–1631. https://doi.org/10.1002/ptr.5174 CrossRef

31.

Maghsoumi-Norouzabad L, Alipoor B, Abed R, Eftekhar Sadat B, Mesgari-Abbasi M, Asghari Jafarabadi M (2016) Effects of Arctium lappa L. (Burdock) root tea on inflammatory status and oxidative stress in patients with knee osteoarthritis. Int J Rheum Dis 19(3):255–261. https://doi.org/10.1111/1756-185X.12477 CrossRefPubMed

32.

Shoara R, Hashempur MH, Ashraf A, Salehi A, Dehshahri S, Habibagahi Z (2015) Efficacy and safety of topical Matricaria chamomilla L. (chamomile) oil for knee osteoarthritis: a randomized controlled clinical trial. Complement Ther Clin Pract 21(3):181–187. https://doi.org/10.1016/j.ctcp.2015.06.003 CrossRefPubMed

33.

Panahi Y, Alishiri GH, Bayat N, Hosseini SM, Sahebkar A (2016) Efficacy of Elaeagnus angustifolia extract in the treatment of knee osteoarthritis: a randomized controlled trial. EXCLI J 15:203–210. https://doi.org/10.17179/excli2015-639 CrossRefPubMedPubMedCentral

34.

Hashempur MH, Sadrneshin S, Mosavat SH, Ashraf A (2018) Green tea (Camellia sinensis) for patients with knee osteoarthritis: a randomized open-label active-controlled clinical trial. Clin Nutr 37(1):85–90. https://doi.org/10.1016/j.clnu.2016.12.004 CrossRefPubMed

35.

Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A (2015) Randomized clinical trial of peganum oil for knee osteoarthritis. J Evid Based Complementary Altern Med 20(2):126–131. https://doi.org/10.1177/2156587214566867 CrossRefPubMed

36.

Ghoochani N, Karandish M, Mowla K, Haghighizadeh MH, Jalali MT (2016) The effect of pomegranate juice on clinical signs, matrix metalloproteinases and antioxidant status in patients with knee osteoarthritis. J Sci Food Agric 96(13):4377–4381. https://doi.org/10.1002/jsfa.7647 CrossRefPubMed

37.

Hashemipour S, Larijani B, Adibi H et al (2004) Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 25(4):38. https://doi.org/10.1186/1471-2458-4-38 CrossRef

38.

Rahnavard Z, Eybpoosh S, Homami MR et al (2010) Vitamin d deficiency in healthy male population: results of the Iranian multi- center osteoporosis study. Iran J Public Health 39(3):45–52PubMedPubMedCentral

39.

Keramat A, Larigani B, Adibi H (2012) Risk factors for spinal osteoporosis as compared with femoral osteoporosis in urban Iranian women. Iran J Public Health 41(10):52–59PubMedPubMedCentral

40.

Ahmadzadeh A, Emam M, Rajaei A, Moslemizadeh M, Jalessi M (2014) Comparison of three different osteoporosis risk assessment tools: ORAI (osteoporosis risk assessment instrument), SCORE (simple calculated osteoporosis risk estimation) and OST (osteoporosis self-assessment tool). Med J Islam Repub Iran 15(28):94

41.

Ebadifardazar AA, Rezapour A, Alipour V, Sarabi-Asiabar A, Gray S, Mobinizadeh M, Yousefvand M, Arabloo J (2017) Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran. Med J Islam Repub Iran 31:39. https://doi.org/10.14196/mjiri.31.39 CrossRef

42.

Hajalilou M, Noshad H, Khabbazi AR, Kolahi S, Azari MH, Abbasneghad M (2012) Familial rheumatoid arthritis in patients referred to rheumatology clinics of Tabriz, Iran. Int J Rheum Dis 15(1):110–115. https://doi.org/10.1111/j.1756-185x.2011.01664.x CrossRefPubMed

43.

Korani S, Korani M, Butler AE, Sahebkar A (2019) Genetics and rheumatoid arthritis susceptibility in Iran. J Cell Physiol 234(5):5578–5587. https://doi.org/10.1002/jcp.27379 CrossRefPubMed

44.

Ghamarzad Shishavan N, Pirouzpanah P, Hajialilo M et al (2016) Risk factors of rheumatoid arthritis development among females in north-west of Iran: a case–control study. Iran Red Crescent Med J 18(12):e26874. https://doi.org/10.5812/ircmj.26874 CrossRef

45.

Davatchi F, Abari IS, Soroosh S, Soroosh M, Sadeghi Abdollahi B (2012) Performance of the 2010 rheumatoid arthritis classification criteria. Int J Rheum Dis 15(5):455–461. https://doi.org/10.1111/j.1756-185X.2012.01766.x CrossRefPubMed

46.

Davatchi F, Akbarian M, Shahram F, Nadji A, Gharibdoost F, Jamshidi AR (2006) DMARD combination therapy in rheumatoid arthritis: 5-year follow-up results in a daily practice setting. APLAR J Rheumatol 9:60–63. https://doi.org/10.1111/j.1479-8077.2006.00166.x CrossRef

47.

Khabbazi A, Kolahi S, Dastgiri S et al (2014) Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate. Int J Rheum Dis 17(6):646–652. https://doi.org/10.1111/1756-185X.12416 CrossRefPubMed

48.

Hajiabbasi A, Shenavar Masooleh I, Alizadeh Y, Banikarimi AS, Ghavidel Parsa P (2016) Secondary Sjogren’s syndrome in 83 patients with rheumatoid arthritis. Acta Med Iran 54(7):448–453PubMed

49.

Shakeri A, Bazzaz MB, Khabbazi A, Fouladi RF (2011) Common carotid intima–media thickness in patients with late rheumatoid arthritis: what is the role of gender? Pak J Biol Sci 14(16):812–816CrossRef

50.

Hajialilo M, Ghorbanihaghjo A, Khabbazi A, Kolahi S, Rashtchizadeh N (2014) Ankylosing spondylitis in Iran; late diagnosis and its causes. Iran Red Crescent Med J 16(4):e11798. https://doi.org/10.5812/ircmj.11798 CrossRefPubMedPubMedCentral

51.

Jamshidi AR, Shahlaee A, Farhadi E, Fallahi S et al (2014) Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis. Mod Rheumatol 24(3):499–504. https://doi.org/10.3109/14397595.2013.844302 CrossRefPubMed

52.

Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A (2008) The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med 11(2):162–165PubMed

53.

Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F (2009) Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med 12(3):279–283PubMed

54.

Akbarian M, Faezi ST, Gharibdoost F et al (2010) Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. Int J Rheum Dis 13(4):374–379. https://doi.org/10.1111/j.1756-185X.2010.01547.x CrossRefPubMed

55.

Nazarinia MA, Ghaffarpasand F, Shamsdin A, Karimi AA, Abbasi N, Amiri A (2008) Systemic lupus erythematosus in the Fars Province of Iran. Lupus 17(3):221–227. https://doi.org/10.1177/0961203307086509 CrossRefPubMed

56.

Espandar G, Moghimi J, Ghorbani R, Pourazizi M, Seiri MA, Khosravi S (2016) Retinal toxicity in patients treated with hydroxychloroquine: a cross-sectional study. Med Hypothesis Discov Innov Ophthalmol 5(2):41–46PubMedPubMedCentral

57.

Hajialiloa M, Ghorbanihaghjo A, Khabbazia A (2014) Nasal carriage rate of Staphylococcus aureus among patients with systemic lupus erythematosus and its correlation with disease relapse. Egypt Rheumatol 37(2):81–84. https://doi.org/10.1016/j.ejr.2014.06.006 CrossRef

58.

Gadakchi L, Hajialilo M, Nakhjavani MR et al (2018) Efficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritis. Iran J Kidney Dis 12(5):288–292PubMed

59.

Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A (2018) Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. Mod Rheumatol 28(3):523–529. https://doi.org/10.1080/14397595.2017.1352479 CrossRefPubMed

60.

Pakfetrat M, Malekmakan L, Kamranpour M, Tadayon T (2017) A five consecutive years’ study of renal function outcome among biopsy proven lupus nephritis patients in Southern Iran. Lupus 26(10):1082–1088. https://doi.org/10.1177/0961203317696588 CrossRefPubMed

61.

Ghafari A, Etemadi J, Ardalan MR (2008) Renal transplantation in patients with lupus nephritis: a single-center experience. Transpl Proc 40(1):143–144. https://doi.org/10.1016/j.transproceed.2007.12.013 CrossRef

62.

González-Serna D, López-Isac E, Yilmaz N et al (2019) Analysis of the genetic component of systemic sclerosis in Iranian and Turkish populations through a genome-wide association study. Rheumatology (Oxford) 58(2):289–298. https://doi.org/10.1093/rheumatology/key281 CrossRef

63.

Yousefi B, Mahmoudi M, Sarafnejad A et al (2017) Downregulation of Aquaporin3 in systemic sclerosis dermal fibroblasts. Iran J Allergy Asthma Immunol 16(3):228–234PubMed

64.

Dashti N, Mahmoudi M, Gharibdoost F et al (2018) Evaluation of ITGB2 (CD18) and SELL (CD62L) genes expression and methylation of ITGB2 promoter region in patients with systemic sclerosis. Rheumatol Int 38(3):489–498. https://doi.org/10.1007/s00296-017-3915-y CrossRefPubMed

65.

Nazarinia MA, Esmaeilzadeh E, Emami Y, Salehi A (2016) One decade distinct features, morbidity and mortality of scleroderma: a cross-sectional study. Clin Exp Rheumatol 100(5):74–78

66.

Poormoghim H, Andalib E, Jalali A, Ghaderi A, Ghorbannia A, Mojtabavi N (2016) Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. Rheumatol Int 36(7):925–934. https://doi.org/10.1007/s00296-016-3475-6 CrossRefPubMed

67.

Hajialilo M, Ghorbanihaghjo A, Khabbazi A et al (2018) Long-term follow-up of 76 Iranian patients with idiopathic inflammatory myopathies. Int J Rheum Dis 21(8):1627–1633. https://doi.org/10.1111/1756-185X.13352 CrossRefPubMed

68.

Naji P, Shahram F, Nadji A, Davatchi F (2010) Effect of early treatment in polymyositis and dermatomyositis. Neurol India 58(1):58–61. https://doi.org/10.4103/0028-3886.60398 CrossRefPubMed

69.

Davatchi F, Jamshidi AR, Tehrani Banihashemi A (2009) Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin Rheumatol 28(11):1275–1282. https://doi.org/10.1007/s10067-009-1235-7 CrossRefPubMed

70.

Alipour S, Nouri M, Sakhinia E et al (2017) Epigenetic alterations in chronic disease focusing on Behcet’s disease: review. Biomed Pharmacother 91:526–533. https://doi.org/10.1016/j.biopha.2017.04.106 CrossRefPubMed

71.

Xavier JM, Davatchi F, Abade O et al (2015) Characterization of the major histocompatibility complex locus association with Behcet’s disease in Iran. Arthritis Res Ther 19(17):81. https://doi.org/10.1186/s13075-015-0585-6 CrossRef

72.

Xavier JM, Shahram F, Davatchi F et al (2012) Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet’s disease. Arthritis Rheum 64(8):2761–2772. https://doi.org/10.1002/art.34437 CrossRefPubMed

73.

Esmaeili M, Bonyadi M, Khabbazi A et al (2011) Common MEFV mutations in Iranian Azeri Turkish patients with Behçet’s disease. Scand J Rheumatol 40(5):383–386. https://doi.org/10.3109/03009742.2011.562532 CrossRefPubMed

74.

Hosseini A, Shanehbandi D, Estiar MA et al (2015) A single nucleotide polymorphism in the FOXP3 gene associated with Behcet’s disease in an Iranian population. Clin Lab 61(12):1897–1903PubMed

75.

Afkari B, Babaloo Z, Dolati S et al (2018) Molecular analysis of interleukin-10 gene polymorphisms in patients with Behcet’s disease. Immunol Lett 194:56–61. https://doi.org/10.1016/j.imlet.2017.12.008 CrossRefPubMed

76.

Alipour S, Sakhinia E, Khabbazi A et al (2018) Methylation status of interleukin-6 gene promoter in patients with Behcet’s disease. Rheumatol Clin. https://doi.org/10.1016/j.reuma.2018.06.006 CrossRef

77.

Alipour S, Nouri M, Khabbazi A et al (2018) Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Behcet’s disease. J Cell Biochem 119(8):6614–6622. https://doi.org/10.1002/jcb.26809 CrossRefPubMed

78.

Kolahi S, Farajzadeh MJ, Alipour S et al (2018) Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-α and CTLA4 genes in patients with Behcet’s disease. Immunol Lett 204:55–59. https://doi.org/10.1016/j.imlet.2018.10.012 CrossRefPubMed

79.

Ahmadi M, Yousefi M, Abbaspour-Aghdam S et al (2019) Disturbed Th17/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet’s disease. J Cell Physiol 234(4):3985–3994. https://doi.org/10.1002/jcp.27207 CrossRefPubMed

80.

Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A et al (2014) The status of serum vitamin D in patients with active Behcet’s disease compared with controls. Int J Rheum Dis 17(4):430–434. https://doi.org/10.1111/1756-185X.12153 CrossRefPubMed

81.

Kolahi S, Khabbazi A, Khodadadi H et al (2015) Vitamin D receptor gene polymorphisms in Iranian Azary patients with Behcet’s disease. Scand J Rheumatol 44(2):163–167. https://doi.org/10.3109/03009742.2014.945477 CrossRefPubMed

82.

Malek Mahdavi A, Khabbazi A, Yaaghoobian B et al (2018) Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. Mod Rheumatol 29:1–7. https://doi.org/10.1080/14397595.2018.1493065 CrossRef

83.

Davatchi F, Shahram F, Chams-Davatchi C et al (2018) Behcet’s disease in Iran: analysis of 7641 cases. Mod Rheumatol 17:1–8. https://doi.org/10.1080/14397595.2018.1558752 CrossRef

84.

Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S (2018) Demographic and clinical features of Behcet’s disease in Azerbaijan. Int J Rheum Dis 21(5):1114–1119. https://doi.org/10.1111/1756-185x.12512 CrossRefPubMed

85.

Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F (2009) Comparison of existing disease activity indices in the follow-up of patients with Behcet’s disease. Mod Rheumatol 19(5):536–541. https://doi.org/10.1007/s10165-009-0191-z CrossRefPubMed

86.

International Team for the Revision of the International Criteria for Behcet’s Disease (ITR-ICBD) (2014) The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. https://doi.org/10.1111/jdv.12107 CrossRef

87.

Davatchi F, Abdollahi BS, Chams-Davatchi C et al (2015) Validation of the revised International Criteria for Behcet’s Disease (ICBD) in Iran. Clin Rheumatol 34(2):315–320. https://doi.org/10.1007/s10067-013-2411-3 CrossRefPubMed

88.

Delnabi L, Gojazadeh M, Hajialilo M, Ebrahimi A, Khabbazi A (2017) Comparison of International Study Group Criteria and International Criteria for Behcet’s Disease in the Azeri population of Iran. J Anal Res Clin Med 5(3):82–85. https://doi.org/10.15171/jarcm.2017.016 CrossRef

89.

Davatchi F, Shahram F, Chams-Davatchi C et al (2010) Behcet’s disease: from East to West. Clin Rheumatol 29(8):823–833. https://doi.org/10.1007/s10067-010-1430-6 CrossRefPubMed

90.

Davatchi F, Sadeghi Abdollahi B et al (2014) Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet’s disease: longitudinal study of up to 10 years. Int J Rheum Dis 17(4):444–452. https://doi.org/10.1111/1756-185X.12248 CrossRefPubMed

91.

Davatchi F, Shahram F, Chams H et al (2003) The influence of the delay of aggressive treatment on the vision and its outcome in Behcet’s disease. Adv Exp Med Biol 3(528):493–494. https://doi.org/10.1007/0-306-48382-3_100 CrossRef

92.

Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M (2016) Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet’s disease. Clin Rheumatol 35(11):2765–2769. https://doi.org/10.1007/s10067-016-3318-6 CrossRefPubMed

93.

Khabbazi A, Karkon Shayan F, Ghojazadeh M et al (2018) Adherence to treatment in patients with Behcet’s disease. Int J Rheum Dis 21(12):2158–2166. https://doi.org/10.1111/1756-185X.13109 CrossRefPubMed

94.

Ebadi N, Shakoori A, Razipour M et al (2017) The spectrum of familial Mediterranean fever gene (MEFV) mutations and genotypes in Iran, and report of a novel missense variant (R204H). Eur J Med Genet 60(12):701–705. https://doi.org/10.1016/j.ejmg.2017.09.007 CrossRefPubMed

95.

Salehzadeh F (2015) Familial Mediterranean fever in Iran: a report from FMF Registration Center. Int J Rheumatol 2015:912137. https://doi.org/10.1155/2015/912137 CrossRefPubMedPubMedCentral

96.

Bagheri M, Rad IA (2017) Analysis of the most common three MEFV mutations in 630 patients with familial Mediterranean fever in Iranian Azeri Turkish Population. Maedica (Buchar) 12(3):169–173

97.

Nobakht H, Zamani F, Ajdarkosh H, Mohamadzadeh Z, Fereshtehnejad S, Nassaji M (2011) Adult-onset familial mediterranean Fever in northwestern Iran; clinical feature and treatment outcome. Middle East J Dig Dis 3(1):50–55PubMedPubMedCentral

98.

Mohammadnejad L, Farajnia S (2013) Mediterranean Fever gene analysis in the Azeri Turk population with familial Mediterranean fever: evidence for new mutations associated with disease. Cell J 15(2):152–159PubMedPubMedCentral

99.

Khabbazi A, Pooraliakbari A, Hajialiloo M, Kolahi S, Sharif S (2011) Study of demographic, clinical and laboratory characteristics of palindromic rheumatism and its frequency in comparison with other inflammatory arthritis in North West of Iran. Med J Tabriz Univ Med Sci 33(2):32–36

100.

Khabbazi A, Hajialiloo M, Kolahi S, Soroosh M, Esalatmanesh K, Sharif S (2012) A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran. Int J Rheum Dis 15(4):427–430. https://doi.org/10.1111/j.1756-185x.2012.01739.x CrossRefPubMed

101.

Khabbazi A, Mirza-Aghazadeh-Attari M, Goli MT, Mahdavi AM, Hajialilo M, Rashtchizadeh N (2019) Is palindromic rheumatism a pre-rheumatoid arthritis condition? Low incidence of rheumatoid arthritis in palindromic rheumatism patients treated with tight control strategy. Rheumatol Clin 1:1. https://doi.org/10.1016/j.reuma.2019.01.002 CrossRef

102.

CINNAGEN. About us. https://www.cinnagen.com/Timeline.aspx?l=3#. Last updated 7 Apr 2019. Accessed 10 May 2019

103.

ARYOGEN. About us. http://www.aryogen.com/FA/index.html. Last updated 7 Feb 2019. Accessed 10 May 2019

104.

Jamshidi A, Gharibdoost F, Vojdanian M et al (2017) A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA^®) to the reference product (Humira^®) in patients with active rheumatoid arthritis. Arthritis Res Ther 19(1):168. https://doi.org/10.1186/s13075-017-1371-4 CrossRefPubMedPubMedCentral

105.

Tabatabaei-Malazy O, Norani M, Heshmat R, Qorbani M et al (2018) Efficacy and safety of the biosimilar recombinant human parathyroid hormone Cinnopar^® in postmenopausal osteoporotic women: a randomized double-blind clinical trial. Iran J Public Health 47(9):1336–1344PubMedPubMedCentral

106.

Toogeh G, Faranoush M, Razavi SM et al (2018) A double-blind, randomized comparison study between Zytux™ vs MabThera^® in treatment of CLL with FCR regimen: non-inferiority clinical trial. Int J Hematol Oncol Stem Cell Res 12(2):84–91PubMedPubMedCentral

Title: Rheumatology training and research in Iran
Authors: Alireza Khabbazi
Mohsen Soroosh
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Osteoarthrosis
Arthritis
Osteoarthrosis
Rheumatoid Arthritis
Palindromic Rheumatism
Published in: Rheumatology International / Issue 8/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04325-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rheumatology training and research in Iran

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2019

Characterization of cell-derived microparticles in synovial fluid and plasma of patients with rheumatoid arthritis

Clinical use of anti-DFS70 autoantibodies

Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review

Quantitative power Doppler signal assessment in the subchondral bone region of the metacarpophalangeal joint is an effective predictor of radiographic progression in the hand of rheumatoid arthritis: a pilot study

Performance of the American College of Rheumatology 2016 criteria for fibromyalgia in a referral care setting

Use of high-resolution vessel wall magnetic resonance imaging in the diagnosis of temporal arteritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page